Application of polycyclic polyketides in preparation of anti-HV (herpes virus) drug

An anti-herpes virus and polyketide compound technology, applied in antiviral agents, pharmaceutical formulations, medical preparations containing active ingredients, etc., can solve the problems of easy mutation, low protein quantity, and high drug resistance

Inactive Publication Date: 2019-09-27
JINAN UNIVERSITY
View PDF1 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the simple structure of the virus itself and the small number of proteins, it is easy to mutate under the repeated action of ant

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of polycyclic polyketides in preparation of anti-HV (herpes virus) drug
  • Application of polycyclic polyketides in preparation of anti-HV (herpes virus) drug
  • Application of polycyclic polyketides in preparation of anti-HV (herpes virus) drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0092] 6,8-dihydroxy-9-isobutyl-2,2,4,4-tetramethyl-4,9-dihydro-1H-xanthene-1,3(2H)-dione intermediate ( 52) Preparation

[0093]

[0094] first step

[0095] At room temperature, dissolve phloroglucinol 52a (2.5g, 20mmol) in nitromethane solution, add anhydrous aluminum chloride (10.7g, 80mmol) and isobutyryl chloride (2.3g, 22mmol) successively, and heat up to reflow. After reacting for 12 hours, the reaction solution was slowly poured into ice water, and saturated sodium potassium tartrate solution (100 mL) was added, followed by vigorous stirring. The reaction solution was extracted 3 times with ethyl acetate (100 mL×3). The organic phases were combined and washed with saturated NaCl solution. After drying and filtering over anhydrous sodium sulfate, the organic phase was evaporated to dryness under reduced pressure. The resulting crude product was separated and purified by silica gel column chromatography to obtain compound 52c (3.6 g, yield 85%).

[0096] second...

Embodiment 2

[0104] 6,8-Dihydroxy-9-cyclobutyl-2,2,4,4-tetramethyl-4,9-dihydro-1H-xanthene-1,3(2H)-dione intermediate ( 53) Preparation

[0105]

[0106] first step

[0107] At room temperature, dissolve phloroglucinol 52a (2.5g, 20mmol) in nitromethane solution, add anhydrous aluminum chloride (10.7g, 80mmol) and cyclobutyryl chloride (2.6g, 22mmol) successively, and heat up to reflow. After reacting for 12 hours, the reaction solution was slowly poured into ice water, and saturated sodium potassium tartrate solution (100 mL) was added, followed by vigorous stirring. The reaction solution was extracted 3 times with ethyl acetate (100 mL×3). The organic phases were combined and washed with saturated NaCl solution. After drying and filtering over anhydrous sodium sulfate, the organic phase was evaporated to dryness under reduced pressure. The obtained crude product was separated and purified by silica gel column chromatography to obtain compound 53c (3.4 g, yield 83%).

[0108] sec...

Embodiment 3

[0116] 6,8-Dihydroxy-5-acetyl-9-isobutyl-2,2,4,4-tetramethyl-4,9-dihydro-1H-oxanthene-1,3(2H)- Preparation of diketone (5)

[0117] At room temperature, compound 52 (44.2mg, 0.1mmol) was dissolved in glacial acetic acid solution (4mL), acetic anhydride (20.6μL, 0.22mmol) and boron trifluoride diethyl ether (13.6μL, 0.105mmol) were added, and the temperature was raised to 100°C. After reacting for 3 hours, the reaction was cooled down to room temperature, 1N aqueous sodium hydroxide solution (4 mL) was added to quench the reaction, and extracted three times with ethyl acetate (8 mL×3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The obtained crude product was recrystallized in a mixture of dichloromethane and n-hexane to obtain compound 5 (16.0 mg, yield 40%).

[0118] 1 H NMR (500MHz, CDCl 3 )δ13.54(s,1H),7.09(s,1H),6.28(s,1H),4.33(t,J=6.1Hz,1H),2.82(s,3H),1.65(s,3H), 1.50(s,3H),1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Half inhibitory concentrationaaaaaaaaaa
Gross weightaaaaaaaaaa
Gross weightaaaaaaaaaa
Login to view more

Abstract

The invention discloses an application of polycyclic polyketides in preparation of an anti-HV (herpes virus) drug. It is found that the polyketides can inhibit diseases caused by infection of four HVs including HSV-1 (herpes simplex virus-1), HSV-2 (herpes simplex virus-2), VZV (varicella zoster virus) and CMV (cytomegalo virus). The compounds show equivalent activity but have different acting mechanisms as compared with commercial drugs such as acyclovir and can overcome drug resistance of existing commercial drugs. Therefore, the compounds have good application prospects in treatment of related diseases caused by infection of HVs including HSV-1, HSV-2, VZV and CMV.

Description

technical field [0001] The present invention relates to a class of medicine for treating and preventing herpes virus infection. More specifically, the present invention relates to a class of polycyclic polyketide compounds used in the preparation of anti-herpes simplex virus type I (Herpes simplex virus-1, HSV-1), herpes simplex virus type II (Herpes simplex virus-1, HSV -2), varicella-zoster virus (Varicellazoster virus, VZV) and cytomegalovirus (Cytomegalo virus, CMV) in the application of four herpes virus drugs. Background technique [0002] Herpes viruses (Herpes viruses, HV) are a class of enveloped viruses with double-stranded DNA genomes. Viruses of this family can spread widely in animals and humans, infect long-term stealth, and induce corresponding diseases. According to the differences in genome sequence, structure and physical and chemical properties, the herpesviruses found to infect humans can be divided into three subfamilies: α-herpesvirinae, β-herpesvirin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/352A61P31/22
CPCA61K31/352A61P31/22
Inventor 叶文才李药兰王英李满妹胡利军唐维程民井苏骏成
Owner JINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap